摘要
HCV在肾移植受者中感染率较高，是影响其术后并发症发生率、移植肾存活率及受者预后生存的主要危险因素之一。近年来的研究表明，HCV感染肾移植受者应用直接抗病毒药物(DAAs)在改善预后、降低术后并发症发生风险及提高移植肾存活率等方面疗效显著，且在感染HCV供者供肾移植的探索性治疗中获益良好，但目前仍需更多高质量实验研究和循证医学的证据进行验证。本文通过对HCV感染与肾脏疾病、肾移植术后并发症、术后DAAs治疗及感染HCV供者供肾应用的研究进展予以综述。
Abstract
Hepatitis C virus infection is highly prevalent in kidney transplant recipients and is one of the major risk factors for postoperative complications, transplant kidney survival and recipient prognosis. Recent studies have shown that the use of direct-acting antiviral agents(DAAs) in kidney transplant recipients is effective in improving prognosis, reducing the risk of postoperative complications and increasing the survival rate of the transplanted kidney, and has been beneficial in the exploratory treatment of hepatitis C virus-positive donor kidney transplants, but more evidence from high-quality trials and evidence-based medicine is still needed. This review provides an overview of research advances in hepatitis C virus infection and kidney disease, post-transplant complications, post-operative DAAs therapy and the use of hepatitis C virus-positive donor kidneys.
基金项目
内蒙古自治区卫生健康科技计划项目(202201304)
内蒙古自治区高等学校科学研究项目(RZ2000001720)
万方数据